1 Ivermectin

Ivermectin (Ive) has exceedingly efficient against several microorganisms including viruses; therefore, it could help as a potential treatment of COVID-19. Because of increasing consumption of ivermectin and vitamin C (Vit.C) in hope to treat ...

FDA To Delete Ivermectin PostsFDA has agreed to remove Ivermectin and COVID related posts from their site, X, Facebook, LinkedIn, etc. Let’s review the repor...

After years of attacks, the FDA has admitted in court that doctors have the right to prescribe Ivermectin. We take a deep look at one of the largest smear campaigns in modern history against a promising therapy. Why did so few medical professionals ignore this early treatment against the warnings of preeminent physicians like Dr. […]

Discovered in the late-1970s, the pioneering drug ivermectin, a dihydro derivative of avermectin—originating solely from a single microorganism isolated at the Kitasato Intitute, Tokyo, Japan from Japanese soil—has had an immeasurably ...

Ivermectin is an antiparasitic drug with a broad spectrum of activity, high efficacy as well as a wide margin of safety. Since 1987, this compound has a widespread use in veterinary medicine and it use has been extended in humans. Here we present a brief ...

Background: Ivermectin has demonstrated different mechanisms of action that potentially protect from both coronavirus disease 2019 (COVID-19) infection and COVID-19-related comorbidities. Based ...

Ivermectin, Buy Ivermectin, Ivermectin Online, buy real Ivermectin tablets, Human Grade Ivermectin

The U.S. Food and Drug Administration (FDA) says a drug called ivermectin does not work against COVID-19 but ...

The microfilaricidal anthelmintic drug ivermectin (IVM) has been used since 1988 for treatment of parasitic infections in animals and humans. The discovery of IVM’s ability to inactivate the eukaryotic importin α/β1 heterodimer ...

Pierre Kory, MD, breaks down the incredible global health impact of ivermectin that led to the awarding of the Nobel Prize in 2015. #GetFactsinated #PierreKory #Ivermectin POSTED: August 30, 2022

President of Front Line Covid-19 Critical Care, Pierre Kory, MD, explains ivermectin’s origin, from a microorganism discovered on a golf course in Japan, to a powerful antiparasitic. #GetFactsinated #PierreKory #Ivermectin POSTED: August 30, 2022

Tested on the Omicron variant, ivermectin outperformed 10 medications, including one approved for emergency use. Early treatment can ...

Dr Tess Lawrie's address to Dr Andrew Hill

POSTED: February 14, 2022

Prominently accountable for the upsurge of COVID-19 cases as the world attempts to recover from the previous two waves, Omicron has further threatened the conventional therapeutic approaches....

When it comes to the treatment of COVID-19, many Western nations have been hobbled by the politicization of ...

The ivermectin docking we identified may interfere with the attachment of the spike to the human cell membrane. Clinical trials now underway should determine whether ivermectin is an effective treatment for SARS-Cov2 infection.

An elderly COVID-19 patient has recovered after a court order allowed him to be treated with ivermectin, despite ...

medRxiv - The Preprint Server for Health Sciences

(NaturalHealth365) Nebraska AG allows doctors to prescribe ivermectin and hydroxychloroquine for COVID-19. Will other states follow?

Link to featured video https://www.youtube.com/watch?v=ctwX1cz_-dw&t=323s Link to Wefwafwa’s channel https://www.youtube.com/channel/UCzsLklGgOttU3Se-WGLp7ow (he needs more subscribers) Link to support Wefwafwa’s work in Africa patreon:https://www.patreon.com/awmedicalvideos Drugs Shown to Inhibit SARS-CoV-2 in COVID-19 Disease: Comparative Basic and Clinical Pharmacology of Molnupiravir and Ivermectin https://austinpublishinggroup.com/pharmacology-therapeutics/fulltext/ajpt-v9-id1149.pdf https://www.linkedin.com/in/leslie-adesuyi-ajayi-md-phd-fbpharmacols-fwacp-69154a38/ There are still many nations where vaccines are not yet widely available, There is a gradual shift in focus, to antiviral drugs, Adjunctive chemoprophylaxis Active treatment of new SARS-CoV-2 infections Post -vaccination breakthrough COVID-19 cases The two ways to get new drugs Develop novel antiviral drugs for SARS-CoV-2 Repurpose existing FDA -approved drugs to treat COVID-19 Ivermectin is the most studied “repurposed” medication globally, in randomized clinical trials, retrospective studies and meta- analyses. Molnupiravir and Ivermectin Anti-SARS- CoV-2 Mechanisms, Pharmacokinetics and Pharmacodynamics Molnupiravir is a broad spectrum antiviral agent against SARS- CoV-2, SARS-CoV, seasonal or pandemic influenza and MERS corona virus Ivermectin is an FDA-approved, WHO essential drug used as broad spectrum antiparasitic, antibiotic and which has demonstrated broad spectrum antiviral activity against RNA viruses, including HIV, Zika, MERS corona virus The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro https://www.sciencedirect.com/science/article/pii/S0166354220302011 5000-fold inhibition of SARS-CoV-2, (99.98% at 48 hours The inhibitory concentration IC50 of Molnupiravir shows it to be a more potent anti-SARS-CoV-2 agent, compared to Ivermectin in vitro. Both molnupiravir and ivermectin are well absorbed after oral dosing Tmax of molnupiravir being 1-1.75 hours, With a half life of 7 hours Tmax of ivermectin is 4-6 hours Very long half life of 81-91 hours Ivermectin, being lipophilic has a large volume of distribution Ivermectin has the ability to accumulate in the lungs The anti-SARS-CoV-2 actions, both of molnupiravir and ivermectin, are dose and concentration dependent Molnupiravir active metabolite (NHC-5’ Triphosphate), acts as a competitive alternative substrate for viral RNA causing viral mutagenesis or mutations, which leads to viral error catastrophe and extinction of replication There is some concern about the safety of NHC -nucleoside triphosphate, which is also mutagenic to mammalian cells Ivermectin, multifarious actions, Binding to SARS-CoV-2 spike protein S Reducing cell entry via human ACE2 receptors Reducing viral transcription Inhibition of cytokine production and inflammation (not yet been shown for molnupiravir) Complimentary pharmacokinetics and pharmacodynamics of the drugs May be additive or synergistic This should be further investigated in anti-SARS- CoV-2 antiviral combination therapy. A combination of molnupiravir with Ivermectin putatively, in effects on RdRP or cytokine release. Cost https://www.who.int/selection_medicines/committees/expert/21/reviews/Ivermectin_Review1.pdf The cost for a package of 100 tablets of 3 mg ivermectin is $2.96. Say, 12mg per day for 5 days = $0.53 Safety http://www.vigiaccess.org https://www.who-umc.org/vigibase/vigibase/ Efficacy Ivermectin https://pubmed.ncbi.nlm.nih.gov/34145166/ For deaths, average risk ratio 0.38, (62% benefit) (moderate-certainty evidence https://ivmmeta.com Early treatment Late treatment Prophylaxis https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015017.pub2/epdf/full Main results, Treating people in hospital with COVID-19 We don't know whether ivermectin compared with placebo or usual care, 28 days after treatment:– leads to more or fewer deaths worsens or improves patients' condition assessed by need for ventilation or oxygen increases or reduces unwanted events Preventing COVID-19 We don't know whether ivermectin leads to more or fewer deaths compared with no drug

Repurposed medicines may have a role against the SARS-CoV-2 virus. The antiparasitic ivermectin, with antiviral and anti-inflammatory properties, has now been tested in numerous clinical trials.We assessed the efficacy of ivermectin treatment in reducing ...

The incredible story of the drug’s discovery, impact and possible future uses. What do penicillin, aspirin and ivermectin have in...

mortality, in secondary outcomes, and in chemoprophylaxis, among people with, or at high risk of, COVID-19 infection. Data sources: We searched bibliographic databases up to April 25, 2021. Two review authors sifted for studies, extracted data, and assessed risk of bias. Meta-analyses were conducted and certainty of the evidence was assessed using the GRADE approach and additionally in trial sequential analyses for mortality. Twenty-four randomized controlled trials involving 3406 participants met review inclusion. Therapeutic Advances: Meta-analysis of 15 trials found that ivermectin reduced risk of death compared with no ivermectin (average risk ratio 0.38, 95% confidence interval 0.19–0.73; n = 2438; I2 = 49%; moderate-certainty evidence). This result was confirmed in a trial sequential analysis using the same DerSimonian–Laird method that underpinned the unadjusted analysis. This was also robust against a trial sequential analysis using the Biggerstaff–Tweedie method. Low-certainty evidence found that ivermectin prophylaxis reduced COVID-19 infection by an average 86% (95% confidence interval 79%–91%). Secondary outcomes provided less certain evidence. Low-certainty evidence suggested that there may be no benefit with ivermectin for “need for mechanical ventilation,” whereas effect estimates for “improvement” and “deterioration” clearly favored ivermectin use. Severe adverse events were rare among treatment trials and evidence of no difference was assessed as low certainty. Evidence on other secondary outcomes was very low certainty. Conclusions: Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally. Address for correspondence: Population Health Sciences Institute, Newcastle University, Baddiley-Clark Building, Richardson Road, Newcastle Upon Tyne NE2 4AX, United Kingdom. E-mail: andy.bryant@ncl.ac.uk The preprint of this review received no funding. This updated version was funded by the crowdfunding initiative https://www.gofundme.com/f/help-us-get-lifesaving-drug-approved-for-covid19 The authors have no conflicts of interest to declare. T. A. Lawrie and A. Bryant cowrote the review; they also sifted the search and classified studies for inclusion and entered and checked the data in RevMan and performed analyses. Data extraction was divided among T. A. Lawrie, A. Bryant, and T. Dowswell. T. Dowswell and A. Bryant graded the evidence. E. J. Fordham prepared the text on ivermectin mechanisms, use in pregnancy, and among the elderly. S. R. Hill prepared the brief economic commentary. Clinicians S. Mitchell and T. C. Tham contributed to the interpretation of the evidence in the discussion and conclusions. All authors reviewed and approved the final version of the manuscript. This article discusses off-label use of the FDA-approved medication ivermectin against COVID-19. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved....

Ivermectin 12 MG is Used to Cure Viral care Infection. #Buy Ivermectin 12 Online and Get [ 12% OFF⭐ + Free Shipping ] World wide✈.